China Universal Asset Management Company’s Mersana Therapeutics MRSN Stock Holding History

China Universal Asset Management Company’s Portfolio MRSN Stock Details MRSN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-875	Closed	-$6.79K	–	518
2025 Q3	$6.79K	Sell	875 -126	-13%	-$945	﹤0.01%	472
2025 Q2	$7.41K	Buy	1,001 +10	+1%	+$88	﹤0.01%	469
2025 Q1	$8.53K	Sell	991 -57	-5%	-$880	﹤0.01%	483
2024 Q4	$37.5K	Buy	+1,048	New	+$54.2K	﹤0.01%	467
2023 Q4	–	Sell	-124	Closed	-$3.93K	–	464
2023 Q3	$3.93K	Buy	124 +64	+107%	+$3.04K	﹤0.01%	403
2023 Q2	$4.93K	Buy	60 +1	+2%	+$146	﹤0.01%	372
2023 Q1	$6.01K	Buy	59 +18	+44%	+$2.53K	﹤0.01%	345
2022 Q4	$5.94K	Buy	41 +5	+14%	+$845	﹤0.01%	278
2022 Q3	$6K	Buy	+36	New	+$5.85K	﹤0.01%	256

Other funds holding MRSN

Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Alamea Verwaltungs Edison, New Jersey $135M AUM 36.32% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

AAA

Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

China Universal Asset Management Company's MRSN Position: Q4 2025 in Review

China Universal Asset Management Company sold out of Mersana Therapeutics (MRSN) in Q4 2025, closing a stake of 875 shares — an estimated $6.79K sold.

China Universal Asset Management Company first reported a position in MRSN in Q3 2022 and held it in 9 quarters. The position peaked at $37.5K in Q4 2024. 51 funds tracked by Wall St. Rank hold MRSN as of Q4 2025.

China Universal Asset Management Company reported no remaining Mersana Therapeutics position as of Q4 2025 after selling out during the quarter.
China Universal Asset Management Company sold 875 Mersana Therapeutics shares in Q4 2025, an estimated $6.79K.
China Universal Asset Management Company first reported a position in Mersana Therapeutics in Q3 2022 and held it in 9 quarters.
China Universal Asset Management Company's Mersana Therapeutics position peaked at $37.5K in Q4 2024.
51 funds tracked by Wall St. Rank held Mersana Therapeutics as of Q4 2025.

Based on China Universal Asset Management Company's 13F filing for Q4 2025, filed 29 Jan 2026.